We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

MipTec - International Life Science Exhibition 2015

  • Messe Basel.
  • Date: Tuesday, September 22, 2015 – Thursday, September 24, 2015

Meet us this year at MipTec in Basel - booth #D59! Come along to discover the newest Promega solutions.
Join the talk by Dr. Mei Cong "Reporter Bioassays to Assess Therapeutic Antibodies in Development for Immunotherapy Programs" on

Tuesday, September 22
12:30 – 13:30
Industry Symposium
Room 4

Reporter Bioassays to Assess Therapeutic Antibodies in Development for Immunotherapy Programs
Mei Cong PhD, Director of CAS, Promega R&D
Department of Research, Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Cancer immunotherapy was named the 2013 “Breakthrough of the Year” by Science, and aims to stimulate a patient’s own immune system to treat cancer. Key inhibitor drugs in the market such as anti-Programmed cell Death protein 1 PD-1 antibodies nivolumab (Opdivo), lambrolizumab (Keytruda), and ipilimumab (Yervoy, an anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antibody) are providing long-term benefits to cancer patients. Traditional inhibitory blockade studies commonly use animal models or freshly isolated peripheral blood mononuclear cells (PBMCs) to quantify antibody drug biological activity. However, animal models can be cost-prohibitive and cell acquisition and preparation is labor intensive and the bioassays incorporating such cells have high inherent variability. Here we demonstrate multiple bioluminescent reporter-based assays that can be used to rapidly measure potencies of multiple biological immunotherapy drugs including PD-1/PD-L1, CTLA4, LAG-3, GITR and CD40. We also demonstrate that these bioassays reflect mode of action of each drug, and quantify potencies of on-market monoclonal antibody drugs for cancer.

Mei Cong is a Director at Promega Research leading a team of scientists in products and custom assay development. It includes reporter vectors, cell lines, as well as other assays and tools based on our luciferase and HaloTag™ protein fusion tag technologies, such as custom NanoBRET™ assays for PPI and target engagement. Mei has recently been focused on leading the development of reporter assays useful for measuring activities of biologic drugs in immunotherapy. Dr. Mei Cong received her Ph.D. in Biochemistry from the University of Arizona. She completed her post-doctoral training on GPCR signal transduction pathway regulation with Dr. Robert Lefkowitz, 2012 Nobel Laureate in Chemistry at Duke University Medical Center. Prior to joining Promega, Mei spent over 14 years in pharma and biotech developing and delivering robust cell-based assays.


Share With a Friend

We will NOT sell your personal information, such as your name or email address, to third parties or use your email address to send you marketing materials. The email and names entered will only be used to identify the sender and recipient of the email.

Send Cancel